Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Pilot Diabetic Foot Ulcer Study

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Regenesis Biomedical, Inc.
ClinicalTrials.gov Identifier:
NCT00761176
First received: September 25, 2008
Last updated: November 3, 2014
Last verified: November 2014
  Purpose

The objective of this study is to compare the reduction in wound surface areas between patients with diabetic ulcers utilizing Provant's pulsed radio frequency energy therapy (PRFE) as an adjunct to standardized basic wound care to those utilizing standardized basic wound care alone.


Condition Intervention
Diabetic Foot Ulcers
Device: The Provant Wound Therapy System

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Single Center Controlled Feasibility Study Comparing Standardized Basic Wound Care to the Provant® Wound Therapy System as an Adjunct to Standardized Basic Wound Care With a Primary Focus on Wound Surface Area Reduction in Diabetic Plantar Foot Wounds

Resource links provided by NLM:


Further study details as provided by Regenesis Biomedical, Inc.:

Primary Outcome Measures:
  • The incidence of wounds reaching complete closure [ Time Frame: approximate one year ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The time to complete wound closure percentage reduction in wound area, percentage reduction in wound volume, and rate of healing mm2/day and mm3/day. [ Time Frame: approximate one year ] [ Designated as safety issue: Yes ]

Enrollment: 30
Study Start Date: July 2008
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Sham
sham of device
Device: The Provant Wound Therapy System
The Provant Wound Therapy System is a safe adjuvant non-invasive medical device.
Other Name: Radio frequency generator devices

Detailed Description:

According to the American Diabetes Association (ADA), there are approximately 20.8 million people in the US with diabetes or 7% of the population (1). A significant number of the diabetic population is prone to pedal ulceration and estimates reveal that 15-20% of this population will develop a foot ulcer in their lifetime.

Treatment of diabetic foot ulcerations have posed a problem to healthcare providers for many years. The literature describes many different modalities for direct wound treatment strategies. Most of these treatments rely on the timely application of biological dressings, offloading of the wound, regular (and often inconvenient) visits to the doctor, and most important, compliance by the patient. It is not uncommon for such wounds to be present for greater than six months, despite use of debridement, off-loading and other basic wound care techniques, before presenting for advanced therapy.

Provant has been selected for study because:

  • It is already indicated for the adjunctive palliative treatment of postoperative pain and edema in superficial soft tissue.
  • It is a non-invasive wound treatment system which utilizes a proprietary PRFE signal which is hypothesized to trigger the release of endogenous growth factors that induce mitosis through accelerating the cell cycle, using a Ca+2 mediated pathway. The result is a significant increase in the rate of cell replication.
  • It has also been shown that PRFE triggers a genetic sequence or cascade of 'wound repair' genes critical for the four stages of wound healing: inflammation, granulation, epithelialization, and remodeling.
  • It has been utilized in the VA Health System since 2004 with no serious adverse events attributable to the device.

This study will assess as an endpoints:

  • Primary - the incidence of wounds reaching complete closure, and
  • Secondary - the time to complete wound closure percentage reduction in wound area, percentage reduction in wound volume, and rate of healing mm2/day and mm3/day.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Males and females > 18 years of age
  2. History of Type 1 or 2 Diabetes Mellitus
  3. A diabetic plantar foot wound, Wagner grade 1 or 2 (See Exclusion Criteria, number four (4).
  4. The qualifying wound must have been present for ≥ 30 days; (the age of the wound will be recorded) based on patient history or documentation in the medical record.
  5. Ankle Brachial Index (ABI) score ≥ 0.7 and ≤ 1.2 with present palpable posterior tibial pulse or dorsalis pedis pulse in index foot
  6. Wound surface area ≥ 1.0 cm2 and ≤ 16.0 cm2
  7. Female subjects of childbearing age will be expected to test negative after taking a serum pregnancy test. Additionally, they must be willing to use an adequate and reliable method of contraception for the study duration. Females who are postmenopausal must have been postmenopausal at least one year or twelve months.

Exclusion Criteria:

  1. Glycosylated Hemoglobin (HbA1c) greater than 12 within 30 days of enrollment
  2. Absent pedal Doppler signals in the foot with the index wound or the presence of significant peripheral artery disease ,
  3. Concurrent treatment of the index wound with another advanced wound care device (i.e. negative pressure wound therapy, non-contact ultrasound, hyperbaric oxygen, electrical stimulation) or pharmaceutical (e.g. growth factors) within thirty (30) days of enrollment.
  4. Index wounds with exposed muscle, ligament or tendon, or which probe to bone regardless of classification—See Inclusion Criteria no. two ( 2).
  5. Wounds due to a nondiabetic etiology (e.g. venous stasis, arterial insufficiency, etc.)
  6. Cellulitis, osteomyelitis, or other clinical evidence of infection involving the index wound.
  7. History of malignancy
  8. Concurrent use of high dose immunosuppressant or cytotoxic drugs
  9. Implanted pacemaker or defibrillator
  10. Metallic implant involving the index foot or ankle
  11. Implanted system with a metallic lead
  12. Pregnant or lactating females
  13. Concurrent participation in another clinical trial. 14) An unwillingness of the patient to comply with the study procedures and the required follow-up regimen.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00761176

Locations
United States, North Carolina
Winston - Salem Outpatient Clinic
Winston - Salem, North Carolina, United States, 27103
Sponsors and Collaborators
Regenesis Biomedical, Inc.
Investigators
Principal Investigator: Mike Wilson, DPM Winston - Salem Outpatient Clinic, WG Hefner VAMC
  More Information

No publications provided

Responsible Party: Regenesis Biomedical, Inc.
ClinicalTrials.gov Identifier: NCT00761176     History of Changes
Other Study ID Numbers: RGI-08-08-1
Study First Received: September 25, 2008
Last Updated: November 3, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Regenesis Biomedical, Inc.:
The study will focus on recalcitrant diabetic foot ulcers that have been present for greater than thirty days.

Additional relevant MeSH terms:
Diabetic Foot
Foot Ulcer
Ulcer
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Diabetic Angiopathies
Diabetic Neuropathies
Endocrine System Diseases
Foot Diseases
Leg Ulcer
Pathologic Processes
Skin Diseases
Skin Ulcer
Vascular Diseases

ClinicalTrials.gov processed this record on November 20, 2014